Document Detail


Statins and peripheral arterial disease: potential mechanisms and clinical benefits.
MedLine Citation:
PMID:  16841271     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Peripheral arterial disease (PAD) is a manifestation of widespread atherosclerosis. Lipid modification (especially with statins) is a component of the treatment of patients with PAD since this condition is considered a coronary heart disease equivalent. This review considers the mechanism of action of statins in PAD. Statins have been shown to reduce the incidence of new coronary events in patients with PAD. However, surveys suggest that many such patients remain undertreated. Statins can also increase walking distance in patients with PAD. There is also evidence that statins can improve renal function in these patients. Several other actions of statins are considered in this review. PAD patients have an increased morbidity and mortality, largely due to myocardial infarction and stroke. Recognizing and treating these high-risk patients as early as possible should be a priority.
Authors:
Mohamad E Alnaeb; Nasser Alobaid; Alexander M Seifalian; Dimitri P Mikhailidis; George Hamilton
Publication Detail:
Type:  Journal Article; Review     Date:  2006-07-14
Journal Detail:
Title:  Annals of vascular surgery     Volume:  20     ISSN:  0890-5096     ISO Abbreviation:  Ann Vasc Surg     Publication Date:  2006 Sep 
Date Detail:
Created Date:  2006-12-13     Completed Date:  2007-02-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8703941     Medline TA:  Ann Vasc Surg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  696-705     Citation Subset:  IM    
Affiliation:
Vascular Unit, Department of Surgery, Royal Free Hospital and University College Medical School, Pond Street, London, NW3 2QG, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antihypertensive Agents / therapeutic use
Atherosclerosis / drug therapy*,  etiology,  physiopathology
Cardiovascular Diseases / etiology,  prevention & control
Endothelium, Vascular / drug effects,  physiopathology
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology,  therapeutic use*
Hyperlipidemias / complications,  drug therapy*
Kidney / drug effects,  physiopathology
Lower Extremity / blood supply*
Peripheral Vascular Diseases / drug therapy*,  etiology,  physiopathology,  prevention & control
Platelet Aggregation Inhibitors / therapeutic use
Risk Factors
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Platelet Aggregation Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Identification of cultured Brachionus rotifers based on RFLP and SSCP screening.
Next Document:  Obstetrician-gynecologists' practice and knowledge regarding spina bifida.